Condition: Multiple Myeloma · Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Mayo Clinic in Arizona - Phoenix | Phoenix, Arizona, United States | Recruiting |
| City of Hope Comprehensive Cancer Center | Duarte, California, United States | Recruiting |
| Mayo Clinic in Florida | Jacksonville, Florida, United States | Recruiting |
| Northside Hospital | Atlanta, Georgia, United States | Recruiting |
| Beth Israel Deaconess Medical Center | Boston, Massachusetts, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Mayo Clinic in Rochester, Minnesota | Rochester, Minnesota, United States | Recruiting |
| University Of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center | Hackensack, New Jersey, United States | Recruiting |
| Roswell Park Cancer Institute | Buffalo, New York, United States | Recruiting |
| Laura and Isaac Perlmutter Cancer Center | New York, New York, United States | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06121843